News
Why This Crypto Could Be the Dogecoin of 2022
Dogecoin (CRYPTO: DOGE) was one of the hottest cryptocurrencies in 2021, running up an amazing 4,000% in a year. What coin might pull off a similar feat in 2022? I'm not particularly bullish on the
3 Top Cloud Stocks to Buy in January
The global cloud computing industry is expected to grow from $219 billion in 2020 to over $791 billion by 2028, according to Fortune Business Insights -- a compound annual growth rate of nearly 18%
Didn't Max Out Your 2021 IRA? Here's Why You Shouldn't Sweat It
You can't rely on Social Security alone to pay your bills in retirement. Those benefits are designed to replace about 40% of the average earner's pre-retirement wages.
But seniors typically need a
3 Best Metaverse Stocks to Buy in 2022 and Beyond
The metaverse has emerged as one of the hottest new growth opportunities in the technology sector. In addition to offering a new medium for socialization and entertainment, virtual worlds could also
3 Biotech Stocks With Major Catalysts in January
This January is going to be a big month for folks with fatty liver disease or need of a COVID-19 vaccine. It's also going to be a month of ups or downs for shareholders of some volatile biotech
Is Snowflake a Good Buy for 2022?
Winter may have arrived, but data warehouse provider Snowflake (NYSE: SNOW) remains a red-hot name on Wall Street. Snowflake, which boasts Salesforce.com and Warren Buffet's Berkshire Hathaway as
Tesla's Blowout Delivery Numbers: These Are Still Early Days
Tesla (NASDAQ: TSLA) shares surged on Monday, following the company's announcement of huge fourth-quarter vehicle delivery numbers. Delivering over 45,000 more vehicles than the consensus analyst
This Big Pharma Stock Is Enriching Shareholders With Its Dividend. But Is It a Buy?
Two signs that a company is focused on creating significant value for its shareholders are when the company boosts its dividend and when it repurchases its shares at attractive valuations.
Better Buy: Novavax vs. Moderna
Novavax (NASDAQ: NVAX) and Moderna (NASDAQ: MRNA) are two of the biotech industry's biggest success stories from the coronavirus vaccine race. While Moderna's market cap of around $104 billion makes
2 Top Growth Stocks New Investors Should Buy in 2022
Getting started in the stock market can be intimidating. With so much to learn and so many companies to research, it's easy to get overwhelmed. My best advice is to read as much as possible, even if
Is This the Best Cryptocurrency to Buy Now?
The crypto market has slowed down some to cap off a big year in 2021, but it's still heading into 2022 with a great deal of excitement and momentum behind it. The big dogs like Bitcoin hit new highs
3 Cryptocurrencies to Buy and Hold Forever
Although 2021 may have been the year that cryptocurrency went mainstream, 2022 looks even more promising for some of the biggest names in crypto.
Crypto can be an intimidating investment, as some
Could Shiba Inu be a Multibagger in 2022?
Shiba Inu (CRYPTO: SHIB) soared an eye-popping 45,000,000% in 2021. At its highest, it climbed more than 109,000,000% from the start of the year. That translates into major gains for investors who
Earn $1,000 of Monthly Retirement Dividends in 6 Easy Steps
In today's low interest rate environment, many investors are looking to stock dividends to provide income from their portfolios instead of more traditional sources like bonds or CDs. As tempting as
Is It Time to Throw in the Towel on Novavax?
Last month, I went out on a limb with a prediction about Novavax (NASDAQ: NVAX). I was right -- and wrong.
On Dec. 14, I wrote that Novavax stock could "soar 20% or more within the next 20 days."
Missed Out on Shiba Inu? Buy This Cryptocurrency Now
Surreal. That's perhaps the best way to describe the performance for Shiba Inu (CRYPTO: SHIB). The digital token skyrocketed in the ballpark of 37,000,000% over the last 12 months. And that's after
3 Crashing Growth Stocks Down 40% in 6 Months That Could Rally in 2022
Buying stocks that have fallen heavily in value can be a risky proposition. You're never really sure where the bottom is and you may stand to lose money in the near term. It's definitely not a great
My Top Cryptocurrency to Buy for 2022 (and It's Not Even Close)
For better or for worse, the 2021 chapter in all our investing journeys has come to a close. Looking ahead, many investors may feel uneasy about buying or even just holding high-priced stocks
3 Stocks to Buy for 2022 That Are Practically Money Machines
Contrary to conventional wisdom, cash is not king. But cash flow is. At least that's the case in investing. Stock valuations are driven primarily by expectations of future cash flows.
Investors
My Top Tech IPO to Buy in January
Globally, the world had a record number of initial public offerings (IPOs) in 2021. According to a report from Ernst & Young, there were 2,388 deals worldwide, and IPOs in the Americas grew 87% year
Exactly How I'd Invest $5,000 If I Had to Start From Scratch Today
There's almost too much information about the stock market out there. It can be confusing to know where to start. There's no one-size-fits-all investing plan, but there's a general outline you can
Meet the 2022 Dogs of the Dow
Many investors are struggling to get income from their investment portfolios right now. Yields on bonds and bank CDs are still at rock-bottom levels, and that's forcing plenty of people into the
Claiming Social Security at Age 70 Will Help You Manage These 3 Retirement Expenses
The decision to sign up for Social Security isn't one to be made lightly. That's because your filing age will dictate how much money you ultimately collect each month.
If you claim Social Security
Why Shares of ImmunoGen Jumped 20.3% in December
ImmunoGen Inc. (NASDAQ: IMGN), an oncology biotech company that specializes in the use of antibody-drug conjugates (ADCs) to make chemotherapy treatments more effective, saw its shares rise by 20.3%
2022 Preview: What's in Store for Bitcoin?
There are some wild predictions of where Bitcoin (CRYPTO: BTC) could be headed from here. On this episode of "The Crypto Show" on Backstage Pass, The Motley Fool's Eric Bleeker and Fool.com